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Abstract: In recent years levobupivacaine, the pure S (−)-enantiomer of bupivacaine, emerged as 
a safer alternative for regional anesthesia than its racemic parent. It demonstrated less afﬁ  nity and 
strength of depressant effects onto myocardial and central nervous vital centers in pharmacodynamic 
studies, and a superior pharmacokinetic proﬁ  le. Clinically, levobupivacaine is well tolerated in a 
variety of regional anesthesia techniques both after bolus administration and continuous postopera-
tive infusion. Reports of toxicity with levobupivacaine are scarce and occasional toxic symptoms 
are usually reversible with minimal treatment with no fatal outcome. Yet, levobupivacaine has not 
entirely replaced bupivacaine in clinical practice. In anesthesia and analgesia practice, levobupivacaine 
and bupivacaine produce comparable surgical sensory block with similar adverse side effects, and 
equal labor pain control with comparable maternal and fetal outcome. The equipotency of the two 
drugs has been recently questioned, prompting clinicians to increase the dose of levobupivacaine 
in an attempt to ensure adequate anesthesia and analgesia and offsetting, therefore, the advantages 
of less motor block with levobupivacaine. In this review we aim to discuss the pharmacological 
essentials of the safer proﬁ  le of levobupivacaine, and analyze the evidence regarding the current 
clinical indications.
Keywords: regional anesthesia, levobupivacaine, pharmacodynamics, pharmacokinetics, 
therapeutic use
Reports of fatalities through cardiovascular toxic effects after regional anesthesia with 
bupivacaine in the late 1970s (Albright 1979) triggered pharmacological research that 
emphasized the selective behavior of the two enantiomers of racemic bupivacaine, ie, 
levo- or S (−)-bupivacaine and dextro- or R (+)-bupivacaine, once in contact with bio-
logical receptors in the body. Levo-enatiomer appeared to have a safer pharmacological 
proﬁ  le than its dextro-partner. Efforts were intensiﬁ  ed to synthesize a pure S (−)-bupi-
vacaine enantiomer, and Chirocaine® (levobupivacaine) Injection (Darwin Discovery 
Ltd., distributed by Purdue Pharma LP, Connecticut, US) was approved by the United 
States Food and Drug Administration in 1999. Ropivacaine (Naropin® (ropivacaine HCL) 
injection, Astra Zeneca Int., distributed by Abraxis BioScience, California, US), another 
pure S (−)-enantiomer, became also available as an alternative to the racemic mixture 
for regional anesthesia. This review discusses the pharmacological rationale behind the 
safer proﬁ  le of levobupivacaine, and its up-to-date use in anesthesia. The descriptors 
bupivacaine, levobupivacaine and dextrobupivacaine are used for the racemic mixture 
and its selective enatiomers, respectively.
Pharmacodynamic foundation of the lesser 
cardiovascular and central nervous toxicity 
of levobupivacaine
In common to all local anesthetics levobupivacaine reversibly blocks the transmission of 
action potential in sensory, motor and sympathetic nervous ﬁ  bers by inhibiting the passage Therapeutics and Clinical Risk Management 2008:4(2) 382
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of sodium through voltage-sensitive ion channels in the neu-
ronal membrane. Whereas the inhibitory action is intended to 
be localized at the site of administration, excessive doses or 
accidental intravascular injection may lead to activity at the 
level of other ion channels in excitable tissues followed by 
unwanted central nervous and cardiovascular adverse effects. 
The current pharmacodynamic evidence from animal and 
human studies suggests that levobupivacaine has a potentially 
greater margin of safety than the racemic bupivacaine.
Cardiovascular toxicity
Levobupivacaine demonstrated less afﬁ  nity and strength of 
inhibitory effect onto the inactivated state of cardiac sodium 
channels than the racemic parent or dextrobupivacaine in in 
vitro animal tissue experimental studies (Vanhouette et al 
1991; Valenzuela et al 1995a). It also showed less depressant 
effect on the atrioventricular conduction (Graf et al 1997) and 
QRS complex duration (Mazoit et al 2000), and provoked 
less impairment of the contractile function of the isolated 
animal heart (Simonetti and Fernandes 1997). Levobupiva-
caine was also less potent in blocking cloned human heart 
sodium and potassium channels (Valenzuela et al 1995b; 
Nau et al 2000).
Similarly, in vivo animal studies showed that the cardio-
toxic dose of intravenous bupivacaine and its pure S (−)-enan-
tiomers followed the order ropivacaine  levobupivacaine 
 bupivacaine (Huang et al 1998; Ohmura et al 2001). The 
estimated mean (standard deviation) fatal dose through severe 
arrhythmias after intravenous administration of levobupiva-
caine in sheep is 277 (51) mg, which is signiﬁ  cantly larger 
than the fatal dose of bupivacaine of 156 (31) mg (Chang 
et al 2000). In regards to the reversibility of cardio-toxic 
effects, evidence is less clear. It was shown in anaesthetized 
open chest dogs receiving a continuous infusion of local 
anesthetic until cardiovascular collapse that animals receiv-
ing bupivacaine were more likely to have a fatal outcome 
than animals receiving levobupivacaine and ropivacaine but 
the differences were not signiﬁ  cant (Groban et al 2001). In 
another study, there was no difference in the number of suc-
cessfully resuscitated anaesthetized rats after the administra-
tion of bupivacaine, levobupivacaine or ropivacaine (Ohmura 
et al 2001). However, less epinephrine was required for the 
successful resuscitation of rats receiving ropivacaine than 
those receiving levobupivacaine or bupivacaine.
Central nervous toxicity
The uptake of bupivacaine by the central nervous cells 
is also enantio-selective. For example, experiments in 
anesthetized rats receiving arrhythmogenic intravenous 
doses of levobupivacaine or dextrobupivacaine showed a 
less rapid blockage of the cell ﬁ  ring in the nucleus tractus 
solitarius after levobupivacaine than after dextrobupi-
vacaine (Denson et al 1992). All animals receiving dex-
trobupivacaine developed apnea and died whereas those 
receiving levobupivacaine continued to breathe and all 
but two survived.
The mean (standard deviation) convulsive dose 
after intravenous levobupivacaine in conscious sheep 
is 103 (18) mg, signiﬁ  cantly higher than the convulsive 
dose of bupivacaine of only 85 (11) mg (Huang et al 1998). 
The convulsive dose of ropivacaine is 155 mg (Nancar-
row et al 1989). The susceptibility for seizure activity 
after intoxication with levobupivacaine and ropivacaine 
is 1.5–2.5 times less than that after racemic bupivacaine 
(Groban 2003).
In human volunteers studies, the mean dose of intravenous 
levobupivacaine and bupivacaine associated with central 
nervous system symptoms was similar, ie, 56–68 mg and 
48–65 mg, respectively (Bardsley et al 1998; Nimmo 1998). 
At this similar dose, levobupivacaine showed signiﬁ  cantly 
less myocardial contractility and atrio-ventricular conduction 
depressant effect than bupivacaine.
Pharmacokinetic foundation 
of the lesser cardiovascular 
and central nervous toxicity 
of levobupivacaine
In human volunteers studies, the volume of distribution and 
overall clearance of levobupivacaine was signiﬁ  cantly lower 
than that of dextrobupivacaine (Burm et al 1994). Never-
theless, the pharmacokinetics of the unbound fraction of 
levobupivacaine accounts for its less toxicity. The unbound 
fraction of levobupivacaine was signiﬁ  cantly lower than 
that of unbound dextrobupivacaine because of its increased 
protein-binding afﬁ  nity. Together with a higher clearance 
of the unbound levobupivacaine, this explains the shorter 
elimination half-life of levobupivacaine while the volume 
of distribution of both unbound drug was similar (Burm 
et al 1994). An increase in postoperative levels of alpha-1-
glycoprotein (Dauphin et al 1997) that binds large amounts 
of levobupivacaine, may further explain the lack of toxicity 
even when large volumes of racemic bupivacaine were admin-
istered in clinical studies (Berrisford et al 1993; Blake et al 
1994; Mather et al 1995). No clinical signs of cardio-vascular 
toxicity were demonstrated despite consistent signiﬁ  cantly Therapeutics and Clinical Risk Management 2008:4(2) 383
Update on levobupivacaine
higher total plasma concentrations of levobupivacaine vs 
dextrobupivacaine.
Various factors such as site of administration, duration of 
continuous infusion and/or addition of agents with vasomotor 
effect may inﬂ  uence the degree of systemic uptake of levobu-
pivacaine. For example, the administration of levobupivacaine 
in paravertebral anesthesia and analgesia was characterized by 
rapid absorption after bolus injection and progressive accumula-
tion after continuous infusion with maximum plasma concentra-
tions at 24 hours (Burlacu et al 2007). A similar rapid absorption 
from the paravertebral space was reported in other studies 
(Berrisfort et al 1993; Perttunen et al 1995), fortunately without 
clinical signs of toxicity. The addition of epinephrine decreased 
peak plasma levels of levobupivacaine after epidural analgesia 
(Kopacz et al 2001). In research carried out by our own group, 
the addition of clonidine to low concentration levobupivacaine 
(0.05%) was followed by a more erratic pattern of systemic 
absorption of levobupivacaine from the paravertebral space, 
which, although did not reach toxic levels, may raise concerns of 
increased potential for toxicity due to the combined vasodilator 
effects of the two drugs (Burlacu et al 2007).
Clinical toxicity and tolerability
Regardless of the type of regional blockade with levobupiva-
caine, 78% of patients may experience at least one adverse effect 
such as hypotension (20%), nausea (12%), postoperative pain 
(18%), fever (17%), vomiting (14%), anemia (12%), pruritus 
(9%), back pain (8%), headache (7%), constipation (7%), diz-
ziness (6%) and fetal distress (5%) (Purdue Pharma L.P.1999). 
The incidence of adverse events with levobupivacaine was 
similar to that after bupivacaine in comparative trials.
The early clinical presentation of toxicity after levobu-
pivacaine appears to consist of central nervous symptoms 
(disorientation, drowsiness, slurred speech), which may cul-
minate with tonic-clonic seizures in some cases (Kopacz and 
Allen 1999a; Pirotta and Spriqqe 2002; Khan and Atanassoff 
2003; Crews and Rothman 2003; Breslin et al 2003). These 
excitatory symptoms are generally self-limiting, or respond 
easily to anticonvulsant treatment. In anaesthetized patients, 
however, sudden cardiovascular collapse may emerge which 
appears to be relatively easily treated with moderate doses 
of sympathomimetics (Salomaki et al 2005).
Levobupivacaine in current regional 
anesthesia practice for surgery
Spinal anesthesia
Because of the small doses of local anesthetic used for 
subarachnoid administration, systemic toxicity is not a 
problem. Not surprisingly therefore, bupivacaine remains 
the most widely and cost-efﬁ  cient long acting local anes-
thetic used in spinal anesthesia. A surgical sensory and 
motor block of similar characteristics and recovery over 
equal dose ranges of levobupivacaine and bupivacaine was 
demonstrated in healthy volunteers (Alley et al 2002) and 
conﬁ  rmed in surgical patients (Glaser et al 2002; Lee et al 
2003; Casati et al 2004a; Fattorini et al 2006) (Table 1). 
The regression of motor block was signiﬁ  cantly more rapid 
after levobupivacaine and ropivacaine than bupivacaine in 
a study by Casati and colleagues, which may be advanta-
geous for early ambulation after day-case surgery (Casati 
et al 2004a).
Traditionally, the dose of levobupivacaine used for spinal 
anesthesia is 15 mg. This dose provides an adequate sen-
sory and motor block for most surgical procedures lasting 
approximate 6.5 hours (Burke et al 1999a). An up-and-down 
sequential design study recommends a minimum effective 
local anesthetic dose (MLAD) of levobupivacaine 11.7 mg 
(Sell et al 2005). Smaller doses (ie, 5–10 mg) have been used 
in ambulatory surgery, and allow a more rapid recovery and 
subsequent discharge home (Breebaart et al 2003, Capelleri 
et al 2005). The addition of fentanyl 15 µg demonstrate a 
sparing effect on the requirement of levobupivacaine while 
maintaining excellent clinical efﬁ  cacy with less hemody-
namic variation (Lee et al 2005) (Table 1).
Epidural anesthesia and analgesia
Table 2 presents a summary of studies regarding the use of 
levobupivacaine in epidural anesthesia and analgesia for 
surgery. The onset of sensory block (8–30 min), maximum 
upper spread (T7-T8 after L2-L3 or L3-L4 lumbar injec-
tion) and duration (4–6 hours) are similar after equal doses 
of levobupivacaine and bupivacaine (15 mL 0.5%) (Cox 
et al 1998a; Casati et al 2003a). The onset of motor block 
is slower with levobupivacaine (Kopacz et al 2000), and 
its quality follows the rank of order bupivacaine  levobu-
pivacaine  ropivacaine (Cox et al 1998a; Kopacz et al 
2000; Casati et al 2003a; Peduto et al 2003). The duration 
of motor block, however, appears to be similar (Cox et al 
1998a; Kopacz et al 2000; Peduto et al 2003). Increasing 
the concentration of levobupivacaine (ie, 15 mL 0.75% vs 
0.5%) prolongs the duration of sensory and motor block 
without increasing the incidence of adverse side effects 
(Cox et al 1998a). However increasing both volume and 
concentration to 20 mL levobupivacaine 0.75% is associated 
with a high incidence of hypotension (82%) and delayed 
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use of a small dose levobupivacaine (5–10 mg/hour) and a 
decline in self-administered analgesia requirements (Kopacz 
et al 1999b; Crews et al 1999). For example, with combined 
morphine background infusion (0.1 mg/hour), the effective 
analgesic dose of levobupivacaine ranges from 8 to 9 mg/hour 
during the ﬁ  rst 24 hours and 7 mg/hour thereafter (Senard 
et al 2004). Similar improved analgesia and local anesthetic 
sparing-effect is noticed when clonidine (8 µg/mL) is added 
to small volume dilute levobupivacaine epidural infusions 
(0.125% 6 mL/hour) (Milligan et al 2000). The motor block 
tends to be denser with clonidine and some degree of arte-
rial hypotension is expected, rarely of clinical importance 
(Milligan et al 2000).
Peripheral nerve blocks
Table 3 summarizes published studies comparing the char-
acteristics of peripheral nerve blocks with levobupivacaine, 
bupivacaine and ropivacaine. A sensory and motor block of 
similar onset (6–10 min) and duration (14–16 hours) fol-
lowed the administration of an equal dose of levobupivacaine 
0.5% or bupivacaine 0.5% in brachial plexus nerve blocks 
(Cox et al 1998b; Liisanantti et al 2004; Duma et al 2005). 
As expected for larger diameter nerves, the onset time of 
sciatic nerve block is delayed to approximate 25–30 min, 
but the average duration remains 14–16 hours (Casati et al 
2002a; Urbanek et al 2003). The quality of sensory and 
motor block appears to be similar in most studies after equal 
doses of levobupivacaine and bupivacaine (Cox et al 1998b, 
Casati et al 2002a,b, 2003b, 2005; Urbanek et al 2003). 
Ropivacaine 0.5% gives a less profound motor block than 
levobupivacaine and bupivacaine (Casati 2003b; Liisanantti 
et al 2004). Higher concentrations of levobupivacaine, ie, 
0.5%–0.75% speed up the onset, and increase the duration 
and quality of peripheral nerves blockade (Cox et al 1998b; 
Urbanek et al 2003; Casati et al 2005). Similar to epidural 
analgesia, continuing the administration of levobupivacaine 
via a peripheral nerve block continuous catheter is associated 
with excellent postoperative analgesia as demonstrated by 
a signiﬁ  cant decline in the postoperative systemic opioids 
requirements (Kean et al 2006).
Adding adjunctive analgesics such as epinephrine, cloni-
dine or opioids to local anesthetic are also used to increase 
the quality of analgesia and improve safety by decreasing 
the requirements of levobupivacaine. The long duration of 
sensory and motor peripheral blockade after levobupivacaine 
of approximate 14–16 hours diminish the clinical importance 
of adding epinephrine to levobupivacaine. However, epineph-
rine may help decrease the potential for systemic toxicity in 
A better way to control the quality and duration of epidu-
ral block with levobupivacaine without excessive motor block 
and hemodynamic consequences is via continuous epidural 
infusion. It was shown that a continuous epidural infusion is 
associated with excellent postoperative analgesia and similar 
recovery of sensory and motor function after equipotent doses 
of levobupivacaine, bupivacaine and ropivacaine (Casati et al 
2003a). The spread, quality and haemodynamic effects are 
also similar after equal doses of levobupivacaine and ropiva-
caine, self-administered via postoperative patient-controlled 
epidural analgesia, but ropivacaine-receiving patients appear 
to ambulate earlier (Senard et al 2004).
The effective dose of epidural levobupivacaine for 
continuous postoperative analgesia approaches 15 mg/hour 
(Murdoch et al 2002). The concentration of levobupivacaine 
solution determines the quality of analgesia, ie, 0.25% 
6 mL/hour providing better analgesia than same volume more 
diluted solutions (0.125% and 0.0625%), although some pro-
longation of the motor blockade may be expected with more 
concentrated solutions (Murdoch et al 2002). Dernedde and 
colleagues encourage the use of large concentration-small 
volume epidural infusion (ie, 3 mL/h levobupivacaine 0.5% 
or 2 mL/hour levobupivacaine 0.75%) which provide similar 
quality of analgesia as the small concentration-large volume 
infusion (10 mL/hour levobupivacaine 0.15%) but with less 
motor block and signiﬁ  cantly increased hemodynamic stabil-
ity (Dernedde et al 2003a,b, 2006). In regards to the mode 
of delivery, patient-controlled epidural top-ups offer the 
advantage of equal quality analgesia with that after continu-
ous infusion, but with less consumption of local anesthetic 
and better motor function (Dernedde et al 2005, 2006). Fur-
thermore, the self-administration of levobupivacaine 15 mg 
either as low concentration large volume (1.5 mg/mL, bolus 
3.3 mL, lockout 20 min) or high concentration small volume 
(5 mg/mL, 1 mL bolus, lockout 20 min) provides an equal 
quality of analgesia with no difference in the incidence of 
side effects (Dernedde et al 2005).
The addition of adjunctive agents (epinephrine, opioids 
or clonidine) to levobupivacaine in epidural anesthesia and 
analgesia may increase the duration and quality of analgesia, 
and further decrease the risk of toxicity. Epinephrine does 
not signiﬁ  cantly inﬂ  uence the onset, spread and duration of 
sensory and motor epidural block, or the systemic absorption 
of levobupivacaine (Kopacz et al 2001). The addition of 
opioids (fentanyl, morphine) to levobupivacaine improves 
analgesia compared to levobupivacaine- or opioid-only 
infusions (Kopacz et al 1999b; Crews et al 1999). It also 
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case of overdose by decreasing systemic absorption through 
vasoconstriction or by signaling the accidental intravascular 
injection. The addition of clonidine to levobupivacaine in 
axillary plexus or psoas compartment was not followed by 
any signiﬁ  cant effect on block’s characteristics and postopera-
tive analgesic requirements (Duma et al 2005; Mannion et al 
2005). In contrast, our group found a signiﬁ  cant decrease in 
postoperative systemic morphine use when clonidine was 
added to levobupivacaine in continuous paravertebral nerve 
block (Burlacu et al 2006). Similarly, we found that the 
addition of fentanyl to levobupivacaine is also followed by 
excellent analgesia as demonstrated by a signiﬁ  cant decrease 
in rescue morphine analgesia. Furthermore, we demonstrated 
that clonidine and fentanyl had a strong local anesthetic spar-
ing effect, as the concentration of levobupivacaine (0.05%) 
used for continuous infusion was the lowest ever used in 
paravertebral block (Burlacu et al 2006).
Levobupivacaine in obstetric 
anesthesia and analgesia
Spinal anesthesia for caesarean section
The concept of pharmacological equipotency of levobupiva-
caine and bupivacaine was challenged in several dose-ﬁ  nding 
studies in obstetric patients receiving spinal anesthesia for 
caesarean section. For example, Khaw and colleagues found 
that levobupivacaine is 38% less potent than bupivacaine, 
with an ED50 and ED95 values of 9.3 and 13.6 mg vs 6.8 
and 9.8 mg, respectively (Khaw et al 2004). Parpaglioni 
and colleagues estimated a similar ED95 levobupivacaine 
of 12.56 mg, whereas the ED95 ropivacaine was 15.97 mg 
(Parpaglioni et al 2006). The above potency hierarchy ie, 
bupivacaine  levobupivacaine   ropivacaine was conﬁ  rmed 
in clinical studies in caesarean section patients (Gautier et al 
2003; Buyse et al 2007). Based on these studies and our own 
experience, we recommend that levobupivacaine 12.5–13.5 
mg should be used for successful spinal anesthesia for caesar-
ean section. A test dose of 10 mg levobupivacaine is sufﬁ  cient 
to conﬁ  rm at 5 min the accidental intrathecal placement of 
an epidural-intended catheter (Camorcia et al 2004).
Analgesia for labor
Minimum effective local anesthetic concentration (MLAC) 
studies using a combined spinal-epidural analgesia tech-
nique (CSE) for labor also conﬁ  rm the potency arrangement 
bupivacaine  levobupivacaine  ropivacaiane for spinal 
sensory block (Camorcia et al 2005). However, the above 
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for labor. Up-and-down sequential allocation studies in 
patients receiving epidural analgesia for labor pain show that 
levobupivacaine and bupivacaine on one side (Lyons et al 
1998), and levobupivacaine and ropivacaine on the other 
side (Polley et al 2003; Benhamou et al 2003) are equipotent. 
One would reasonably assume that the three local anesthetics 
are equipotent. Intriguingly however, in other similar design 
studies (Polley et al 1999; Capogna et al 1999), ropivacaine 
was found to be 40% to 50% less potent than bupivacaine. 
The minimum effective local anesthetic concentration of 
levobupivacaine for motor block (MMLAC) is signiﬁ  cantly 
greater than that of bupivacaine indicating that levobupiva-
caine is less potent at motor block than bupivacaine when 
administered in epidural analgesia for labor (Lacassie and 
Columb 2003).
The relative potency of the three most commonly used 
drugs in obstetric anesthesia remains to be further elucidated, 
but the current evidence from MLAC and MMLAC studies 
suggest a potency hierarchy of bupivacaine  levobupivacaine 
 ropivacaine. However, the epidural and spinal MLAC or 
MMLAC studies estimate the concentration at which only 
50% of laboring patients will have adequate pain control 
with minimal motor block. In clinical practice, anesthetists 
are inclined to administer larger doses of local anesthetic 
to ensure adequate pain relief in the majority of patients. 
Because of the variety of doses and adjunctive analgesics 
combinations used in clinical studies (Table 4), the rank of 
order established by the MLAC studies is not always easy 
to corroborate (Burke et al 1999b; Convery et al 1999; 
Purdie and McGrady 2004; Lim et al 2004a; Suspandji et al 
2004).
Table 4 also shows the results of several studies using 
levobupivacaine combined with opioids with or without 
epinephrine in epidural or CSE analgesia in labor. In particu-
lar, the addition of fentanyl to levobupivacaine prolongs the 
duration and increases the success rate of the sensory block 
after intrathecal administration in a CSE analgesia technique 
(Lim et al 2004b). A local anesthetic sparing effect of fentanyl 
is also demonstrated as intrathecal levobupivacaine 1.25 mg 
with fentanyl 12.5 µg was followed by effective analgesia 
with less motor block compared with a double dose of each 
drug (Chang and Chiu 2004). The addition of epinephrine 
to a mixture of levobupivacaine and opioid increased the 
success rate of sensory block but appeared to also increase 
the frequency of motor blockade (Soetens et al 2006).
In our experience, using an epidural bolus of 10 mL 
levobupivacaine 0.2%–0.25% followed by epidural infu-
sions or top-ups of low concentrations levobupivacaine 
(ie, 0.1%–0.125%) combined with opioids based on institu-
tionally designed protocols, provides the same good quality 
labor analgesia as bupivacaine, but possibly with less motor 
block. A combined spinal-epidural technique with intrathe-
cal levobupivacaine 1.2–2.5 mg combined with small dose 
opioid (eg, fentanyl 12.5–25 µg) provides excellent prolonged 
sensory block with minimum motor blockade.
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